»çÀÌÆ®¸Ê
ÀÌ¿ë¾È³»
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç
Ȩ
Ä«Å×°í¸®
¸ÂÃãÇü½ÃÀåÁ¶»ç
±¹Á¦ÄÁÆÛ·±½º
±Û·Î¹ú ÆÄÆ®³Ê
¸ÞÀϸµ ¼ºñ½º
ȸ»ç¼Ò°³
°æ¿µÀ̳ä
»ç¾÷¿µ¿ª
ÁöÁ¡¾È³»
°í°´»ç ¸ñ·Ï
±Û·Î¹ú ÆÄÆ®³Ê
ÀÌ¿ë¾à°ü
Contact Us
Ȩ
>
±Û·Î¹ú ÆÄÆ®³Ê
>
L
> La Merie Publishing
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
Y
Z
La Merie Publishing
½ºÆäÀÎ ¹Ù¸£¼¿·Î³ª¿¡ º»»ç¸¦ µÐ La Merie´Â ¹ÙÀÌ¿À Å×Å©³î·¯Áö ¹× Á¦¾à »ê¾÷¿¡ ´ëÇÑ ¸®¼Ä¡¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù.
Á¦¸ñ °Ë»ö
1
-
25
¸®ºä (Àüü£º
32
°Ç)
Á¤·Ä
¹ßÇàÀÏ
ÇѱÛÁ¦¸ñ
¿µ¹®Á¦¸ñ
¸®¼Ä¡»ç
°¡°Ý
Ç¥½Ã °Ç¼ö
25
50
100
1
2
´ÙÀ½
GLP-1(Glucagon-Like Peptide-1) ¼ö¿ëü ÀÛ¿ëÁ¦ : Ç¥Àû ÆÄÀÌÇÁ¶óÀÎ ¹× ÀÌÇØ°ü°èÀÚ ºÐ¼®(2012³â)
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
»óǰÄÚµå :235119
GLP-1(Glucagon-Like Peptide-1) ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ »ó¾÷Àû Ãø¸é°ú ÀÓ»ó ºÐ¾ßÀÇ µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2Çü ´ç´¢º´ÀÇ ÀÎÅ©·¹Æ¾¿¡ ÀÇÇÑ Ä¡·á µ¿Çâ, Ä¡·á ºñ¿ë, ÀÇ»çÀÇ ±âÈ£, ȯÀÚ Àα¸, GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ ºñÁö´Ï½º ȯ°æ, GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 2,600
¹ßÇàÀÏ
2012³â 03¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
231 Pages
°æÀï ºÐ¼® : Ç×°¨¿° Ç×ü
Competitor Analysis: Anti-Infective Antibodies
»óǰÄÚµå :224082
ÀçÁ¶ÇÕ ´ÜÀÏŬ·ÐÇ×ü ¹× ´ÙÁßŬ·ÐÇ×ü(Recombinant Mono or polyclonal Antibodies), »ç¶÷ Ç÷Àå À¯·¡ ¸é¿ª±Û·ÎºÒ¸°(Human Plasma-derived Immunoglobulins)¿¡ °ü·ÃµÈ °¢ ±â¾÷¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÇöÀçÀÇ R&D °ü·Ã ÇÁ·ÎÁ§Æ® µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,086
¹ßÇàÀÏ
2011³â 11¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
160 Pages
°æÀï ºÐ¼® : ¾Ï¹é½Å
Competitor Analysis: Cancer Vaccines
»óǰÄÚµå :221876
¾Ï ¿¹¹æ ¹× Ä¡·á¿ë ¹é½ÅÀ» Á¶»çÇϰí, ¿¬±¸ °³¹ßÁßÀÎ ÇöÀç ÁøÇàÁß ÇÁ·ÎÁ§Æ®ÀÇ °³¿ä, °æÀï»çº° µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 964
¹ßÇàÀÏ
2011³â 11¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
ÅçÀ¯»ç¼ö¿ëü(TLR) ÀÛ¿ëÁ¦ ¹× ±æÇ×Á¦ ½ÃÀåÀÇ °æÀï ºÐ¼®
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
»óǰÄÚµå :216726
¾Ï, °¨¿°º´, ÆÐÇ÷Áõ, ¾Ë·¹¸£±âÀÇ Ä¡·á¿Í ¿¹¹æÀ» À§ÇØ ÅçÀ¯»ç¼ö¿ëü(TLR : Toll-Like Receptor)¸¦ Ç¥ÀûÀ¸·Î ÇÑ ¼ÒºÐÀÚ, ´Ü¹éÁú, DNA, RNA, ¹é½Å °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ´ëÇØ ºÐ¼®Çϰí, ÀÛ¿ëÁ¦ ¹× ±æÇ×Á¦, Ç׿øº¸°Á¦(Adjuvant) ¹× ¹é½Å ¿¬±¸°³¹ß ÇöȲ°ú ÇâÈÄ ¿¹ÃøÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 800
¹ßÇàÀÏ
2011³â 10¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
152 Pages
¹é½Å ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º : 1³â Á¤±â ±¸µ¶
Vaccine Pipeline Database: 1-Year Subscription
»óǰÄÚµå :216725
Ãâ½Ã¿Ï·á ¹× ¿¬±¸°³¹ßÁßÀÎ ¿¹¹æ ¹× Ä¡·á ¹é½Å 1,200°³ ÇÁ·ÎÁ§Æ®¿¡ ¿Â¶óÀÎÀ¸·Î Á¢¼ÓÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅͺ£À̽º·Î, °¢ ÇÁ·ÎÁ§Æ®ÀÇ Ç¥Àû°ú ÀÛ¿ë±â¼, Ä¡·á ºÐ¾ß µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,333
¹ßÇàȽ¼ö
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
Ç×ü-¾à¹° º¹ÇÕü(2011³â) - ´Ù°¡¿À´Â ºñ¾àÀû Áøº¸ : ±â¼ú, ÀÌÇØ°ü°èÀÚ, ¿¬±¸ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
»óǰÄÚµå :214059
Ç×ü-¾à¹° º¹ÇÕü(Antibody-Drug Conjugates)¿¡¼ ÀÌ¿ëµÇ´Â ±â¼ú, ÀÌÇØ°ü°èÀÚ, ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ, »ó¾÷Àû °¡Ä¡, ±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 2,632
¹ßÇàÀÏ
2011³â 09¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
274 Pages
CÇü °£¿°ÀÇ Ç¥Àû ¿ä¹ý
Competitor Analysis: Targeted Therapy of Hepatitis C
»óǰÄÚµå :214060
CÇü °£¿°(Hepatitis C)À» À§ÇÑ Ç×¹ÙÀÌ·¯½º Ä¡·á¿¡ ´ëÇØ ºÐ¼®ÇÏ°í »õ·Î¿î Ç¥ÀûÀ» À§ÇÑ ºÐÀÚ ¿¬±¸ °³¹ß ÇöȲ°ú ±â¾÷º° ÆÄÀÌÇÁ¶óÀο¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 826
¹ßÇàÀÏ
2011³â 08¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
91 Pages
°æÀï ºÐ¼® : PI3K-AKT-mTOR ÀúÇØÁ¦
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
»óǰÄÚµå :203065
¾Ï ¹× ¿©Å¸ ÀûÀÀ¿¡¼ÀÇ PI3K-AKT-mTOR ÀúÇØÁ¦ ¿¬±¸°³¹ß ÇÁ·ÎÁ§Æ®¿Í ±â¾÷º° ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 711
¹ßÇàÀÏ
2011³â 06¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
100 Pages
°æÀï ºÐ¼® : ÀÎÇ÷翣ÀÚ ¹é½Å
Competitor Analysis: Influenza Vaccines
»óǰÄÚµå :193884
°èÀý¼º ÀÎÇ÷翣ÀÚ ¹× À¯Ç༺ ÀÎÇ÷翣ÀÚ¿¡ ´ëÇØ ÇöÀç Ãâ½ÃµÈ ¹é½Å°ú ¿¬±¸°³¹ßÁßÀÎ ÇÁ·ÎÁ§Æ®, ±â¾÷º° Á¦Ç° Æ÷Æ®Æú¸®¿À, ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 718
¹ßÇàÀÏ
2011³â 05¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
123 Pages
´ç´¢º´ÀÇ Ç¥ÀûÄ¡·á
Competitor Analysis: Targeted Therapy of Diabetes
»óǰÄÚµå :180347
1Çü¡¤2Çü ´ç´¢º´ÀÇ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ºÐÀÚ ºÐ¾ß¿¡¼ÀÇ °æÀï µ¿ÇâÀ» ºÐ¼®ÇÏ°í ºÎ¹®º°(Àν¶¸°, PPAR ÀÛµ¿Á¦, DPP-IV ÀúÇØÁ¦, GLP-1 ¾Æ³¯·Î±×, SGLT ÀúÇØÁ¦ µî) µ¿Çâ, ÇöÀçÀÇ ¿¬±¸ °³¹ß ÇÁ·ÎÁ§Æ®¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,736
¹ßÇàÀÏ
2011³â 04¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
114 Pages
´ç´¢º´ÀÇ »õ·Î¿î Ä¡·áÁ¦
Competitor Analysis: Emerging Diabetes Drugs
»óǰÄÚµå :180346
1Çü ¹× 2Çü ´ç´¢º´À» À§ÇÑ Ä¡·á¾àÁ¦ °³¹ß µ¿ÇâÀ» ºÐ¼®ÇÏ°í °¢ ±â¾÷ÀÇ ¿¬±¸°³¹ß Æ÷Æ®Æú¸®¿À, ÇöÀç Èû ½ñ°í ÀÖ´Â ÇÁ·ÎÁ§Æ®ÀÇ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 868
¹ßÇàÀÏ
2011³â 04¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
104 pages
RNA Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º : ¿¬°£ Á¤±â ±¸µ¶
RNA Therapeutics Pipeline Database: 1-Year Subscription
»óǰÄÚµå :177919
¾ÈƼ¼¾½º(Antisense), ¾ÐŸ¸Ó(Aptamers), siRNA, RNAi, LNA RNA µî Ãâ½ÃµÇ¾î ÀÖ´Â, ¶Ç´Â ¿¬±¸°³¹ßÁßÀÎ RNA Ä¡·áÁ¦¿¡ °üÇÑ Á¤º¸¿Í °¢ ÇÁ·ÎÁ§Æ®¸¦ ¿µ¿ªº°, Ä¡·áºÐ¾ßº°, ¿¬±¸°³¹ß ´Ü°èº°·Î ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 847
¹ßÇàÀÏ
2011³â 03¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
°æÀï ºÐ¼® : ÀÎÅÍÆä·Ð
Competitor Analysis: Interferon
»óǰÄÚµå :203764
°¨¿°Áõ, ¾Ï, ´Ù¹ß¼º °æÈÁõ Ä¡·á¸¦ À§ÇÑ ÀÎÅÍÆä·Ð(Interferon) ¥á,¥â,¥ã µîÀÇ °³¹ß ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Ãâ½Ã ÀÎÅÍÆä·Ð¿¡ °üÇÑ Á¤º¸, ÇöÀç Ȱ¹ßÇÑ ¿¬±¸°³¹ß ÇÁ·ÎÁ§Æ®, ±â¾÷º° Æ÷Æ®Æú¸®¿À ¹× ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 653
¹ßÇàÀÏ
2011³â 02¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
Á¶±â ÀÓ»ó °³¹ßÀÇ ¾ÏÇ×ü
Competitor Analysis: Cancer Antibodies in Early Clinical Development
»óǰÄÚµå :166719
¾ÏÄ¡·á¸¦ À§ÇÑ Ç×ü °³¹ß°ú Á¶±â ÀÓ»ó °³¹ß¿¡¼ ÇöÀç ÁøÇàµÇ°í ÀÖ´Â ÇÁ·ÎÁ§Æ®, ±â¾÷º° ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,210
¹ßÇàÀÏ
2011³â 02¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
183 Pages
Ä¡·á¿ë ´Ü¹éÁú ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º : 1³â Á¤±â ±¸µ¶
Therapeutic Protein Pipeline Database: 1-Year Subscription
»óǰÄÚµå :166718
1,700°Ç ÀÌ»óÀÇ Ãâ½Ã¿Ï·á ¶Ç´Â ¿¬±¸°³¹ß ´Ü°è¿¡ ÀÖ´Â Ä¡·á¿ë ´Ü¹éÁú ÇÁ·ÎÁ§Æ®¿¡ ¿Â¶óÀÎÀ¸·Î Á¢±ÙÇßÀ¸¸ç, °¢ ÇÁ·ÎÁ§Æ®º° Ç¥Àû ¹× ÀÛ¿ë±â¼, Ä¡·á ºÐ¾ß, ¿¬±¸°³¹ß ´Ü°è µîÀ» »ó¼¼È÷ Á¤¸®Çß½À´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,613
¹ßÇàȽ¼ö
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
Ä¡·á¿ë ´Ü¹éÁú : ¹ÙÀÌ¿À½Ã¹Ð·¯, ¹ÙÀÌ¿Àº£ÅÍ, ¹ÙÀÌ¿À¼öÇǸ®¾î
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
»óǰÄÚµå :146105
ÇöÀç ¹ÙÀÌ¿À½Ã¹Ð·¯(Biosimilars), ¹ÙÀÌ¿Àº£ÅÍ(Biobetters), ¹ÙÀÌ¿À¼öÇǸ®¾î(Biosuperiors) Ä¡·á¿ë ´Ü¹éÁúÀÇ ¿¬±¸ °³¹ß µ¿ÇâÀ» ºÐ¼®ÇÏ°í ºñ´Ü¹éÁú Á¦Ç°°ú Çã°¡ ¾àÁ¦ÀÇ °³¿ä, °æÀï ±â¾÷ÀÇ ÇÁ·ÎÁ§Æ® ³»¿ë µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 2,187
¹ßÇàÀÏ
2011³â 02¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
265 Pages
°æÀï ºÐ¼® : ¿°Áõ¼º Áúȯ ¹× ÀÚ°¡¸é¿ªÁúȯÀ» À§ÇÑ Ç×üġ·á
Competitor Analysis: Antibody Therapy of Inflammatory and Autoimmune Diseases
»óǰÄÚµå :142936
¿°Áõ¼º Áúȯ(Inflammatory Diseases) ¹× ÀÚ°¡¸é¿ªÁúȯ(Autoimmune Diseases)À» À§ÇÑ Ç×üġ·á(Antibody Therapy)¿¡ °ü·ÃµÈ ¿¬±¸°³¹ß µ¿ÇâÀ» ºÐ¼®Çϰí, ±â¾÷º° ÆÄÀÌÇÁ¶óÀÎ(Pipeline), °¢»ç°¡ ÇöÀç ÁøÇàÇϰí ÀÖ´Â ÇÁ·ÎÁ§Æ® °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,184
¹ßÇàÀÏ
2010³â 12¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
172 Pages
Ç×ü ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º
Antibody Pipeline Database
»óǰÄÚµå :138240
¼¼°è¿¡¼ °³¹ßÁßÀÎ 1,600°Ç ÀÌ»óÀÇ Ä¡·á¿ë Ç×ü(Antibody) µ¥ÀÌÅͺ£À̽º¸¦ ¿Â¶óÀÎ ¾×¼¼½º¸¦ ÅëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,638
¹ßÇàÀÏ
2010³â 11¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
Ç×ü ±â¼ú ±â¾÷ (2010³â)
Antibody Technology Companies 2010
»óǰÄÚµå :136603
2009³âÀÇ Ç×ü ½ÃÀå °³¿ä¿Í 37°³ÀÇ ½ÂÀÎ ¿Ï·áµÈ Ä¡·á¿ë Ç×ü Á¦Ç°ÀÇ ±â¼ú °³¿ä, ½ÃÀå ÁøÃâ ±â¾÷ 96°³»çÀÇ °³¿ä, ÆÄÀÌÇÁ¶óÀÎ(Pipeline) µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,394
¹ßÇàÀÏ
2010³â 11¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
283 pages
°æÀï ºÐ¼® : ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í ¹ÙÀÌ¿Àº£ÅÍ ¹× Biosuperior Ç×ü
Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies
»óǰÄÚµå :134392
¹ÙÀÌ¿À½Ã¹Ð·¯(Biosimilar) ¹× ¹ÙÀÌ¿Àº£ÅÍ(Biobetter), Biosuperior Ç×üÀÇ ÃֽŠ¿¬±¸°³¹ß µ¿ÇâÀ» Á¤¸®Çϰí, ±â¾÷º° ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ ¹× ÇÁ·ÎÁ§Æ® °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 961
¹ßÇàÀÏ
2010³â 10¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
106 Pages
ÀÀ°íÀÎÀÚ(2010³â) : ÁöÇ÷ ´Ü¹éÁúÀÇ °æÀï ȯ°æ ¹× ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins
»óǰÄÚµå :134089
ÀÀ°íÀÎÀÚ ºÐ¾ß¿¡ °üÇÑ ¿¬±¸°³¹ß °³¿ä, °¡Àå À¯¸ÁÇÑ ÀÀ°íÀÎÀÚÀÇ °³¿ä, ´Ü¹éÁú ¿£Áö´Ï¾î¸µ, ½ÃÀå¿¡¼ Ȱ¾àÁßÀÎ ±â¾÷ 50°³»çÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 3,346
¹ßÇàÀÏ
2010³â 09¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Å¸¿ì ¹× ¾Æ¹Ð·ÎÀÌµå º£Å¸ Ç¥Àû¿ä¹ý
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease
»óǰÄÚµå :127639
¾ËÃ÷ÇÏÀ̸Ӻ´(Alzheimer''s Disease)ÀÇ Å¸¿ì(Tau) ¹× ¾Æ¹Ð·ÎÀÌµå º£Å¸(Amyloid Beta)¸¦ Ç¥ÀûÀ¸·Î ÇÑ Ä¡·á ¹é½Å, Ç×ü, ÀúºÐÀÚ ºÐ¾ß¸¦ ºÐ¼®Çϰí, ±â¾÷ÀÇ ¿¬±¸°³¹ß µ¿ÇâÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 890
¹ßÇàÀÏ
2010³â 08¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
105 Pages
¾ÏÄ¡·áÁ¦ÀÇ Pipeline Database
Oncology Pipeline Database
»óǰÄÚµå :113796
¾ÏÄ¡·áÁ¦ÀÇ Pipeline µ¿ÇâÀ» Á¶»ç ºÐ¼®Çϰí 3,000°ÇÀÌ ³Ñ´Â ÇÁ·ÎÁ§Æ®ÀÇ °¢Á¾ µ¥ÀÌÅ͸¦ ¿Â¶óÀÎ µ¥ÀÌÅͺ£À̽º·Î Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 2,509
¹ßÇàÀÏ
2010³â 02¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
°æÇÕ ºÐ¼® : Á¶Á÷ ¼ºÀåÀÎÀÚ
Competitor Analysis: Tissue Growth Factors
»óǰÄÚµå :108186
Á¶Á÷ ¼ºÀå°ú ¼öº¹À» Á÷Á¢Àû, °£Á¢ÀûÀ¸·Î ÀÚ±ØÇÏ´Â ÇÁ·ÎÅ×ÀÎ, ÆéƼµå, Ç×ü, DNA, RNA, ¼¼Æ÷, ¼ÒºÐÀÚÀÇ ¿¬±¸ °³¹ß ÇöȲÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,131
¹ßÇàÀÏ
2009³â 12¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
57 Pages
°æÇÕ ºÐ¼® : Ç÷¾×ÀÀ°íÀÎÀÚ
Competitor Analysis: Coagulation Factors
»óǰÄÚµå :102247
À¯Àü¼º/ÈÄõ¼º Ç÷¾×ÀÀ°í Àå¾Ö Ä¡·á¿¡ ÀÖ¾î¼ ±¹¼Ò/Àü½Å Åõ¿©¿ë Ç÷ÀåÀ¯·¡/ÀçÁ¶ÇÕ Ç÷¾×ÀÀ°íÀÎÀÚ Á¦ÀçÀÇ ºÐ¾ß¿¡ ´ëÇÑ °æÇÕ Æò°¡¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 705
¹ßÇàÀÏ
2009³â 10¿ù
¸®¼Ä¡»ç
La Merie Publishing
ÆäÀÌÁö¼ö
126 Pages
1
2
´ÙÀ½
»ó±â ÀÚ·á ÀÌ¿ÜÀÇ
La Merie Publishing
ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï
¹®ÀÇ
ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.